Arava and Pulmonary oedema aggravated - a phase IV clinical study of FDA data

Summary:

Pulmonary oedema aggravated is reported as a side effect among people who take Arava (leflunomide), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Actemra, and have Juvenile rheumatoid arthritis.

The phase IV clinical study analyzes which people have Pulmonary oedema aggravated when taking Arava. It is created by eHealthMe based on reports of 75,674 people who have side effects when taking Arava from the FDA, and is updated regularly.

What is Arava?

Arava has active ingredients of leflunomide. It is often used in rheumatoid arthritis. eHealthMe is studying from 76,040 Arava users. Check the latest studies of Arava.

What is Pulmonary oedema aggravated?

Pulmonary oedema aggravated (fluid accumulation in the lungs) is found to be associated with 1,582 drugs and 680 conditions by eHealthMe. Check the latest studies of Pulmonary oedema aggravated.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

75,674 people reported to have side effects when taking Arava.
Among them, 213 people (0.28%) have Pulmonary oedema aggravated.

Could Arava cause Pulmonary oedema aggravated?

Among these 213 people:

How long have people been on Arava when they have Pulmonary oedema aggravated? *

Click here to view more results

What is the gender of people who have Pulmonary oedema aggravated when taking Arava? *

Click here to view

What is the age of people who have Pulmonary oedema aggravated when taking Arava? *

Click here to view more results

* Approximation only. Some reports may have incomplete information.

Do you take Arava and have Pulmonary oedema aggravated?

- Check whether Pulmonary oedema aggravated is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Arava:

Arava (76,040 reports)

Pulmonary oedema aggravated treatments and more:

Pulmonary oedema aggravated (12 reports)

How severe was Pulmonary oedema aggravated and when was it recovered:

Pulmonary oedema aggravated in Arava

Expand to all the drugs that have ingredients of leflunomide:

Pulmonary oedema aggravated and drugs with ingredients of leflunomide (382 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Arava:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pulmonary oedema aggravated:

Pulmonary oedema aggravated (1,582 drugs)

Browse all the conditions that are associated with Pulmonary oedema aggravated:

Pulmonary oedema aggravated (680 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on leflunomide (the active ingredients of Arava) and Arava (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.